Bydgoszcz

• This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics … Ended recruitment
  2023-510061-10-00 3 2023-01-09 Clear cell renal cell carcinoma (ccRCC, first-, second- and third-line
• Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Ended recruitment
  2024-512915-33-00 5 2022-12-22 Metastatic Colorectal Cancer
• Study to evaluate the long-term safety of GT005 in participants having macular degeneration that led to geographic atrophy in their eyes and … Ended recruitment
  2024-510946-15-00 9 2022-12-08 Geographic atrophy (GA) secondary to age-related macular degeneration
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504741-32-00 4 2022-11-30 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit … Ended recruitment
  2023-504743-13-00 4 2022-11-30 Moderately to Severely Active Ulcerative Colitis
• Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Ended recruitment
  2023-508284-77-00 5 2022-11-16 Generalized Myasthenia Gravis with autoantibodies against acetylcholin
• A study into the efficacy and safety of dazucorilant (CORT113176) in patients with Amyotrophic Lateral Sclerosis Ended recruitment
  2024-514082-19-00 4 2022-11-04 Amyotrophic Lateral Sclerosis
• A Phase III Open-Label Trial of Acalabrutinib Plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocyti … Ended recruitment
  2023-505866-27-00 5 2022-10-28 Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
• A Phase 3 study of Tafasitamab plus Lenalidomide in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Ended recruitment
  2023-505579-53-00 5 2022-10-25 Diffuse large B-cell lymphoma (DLBCL)
• A research study to see how well CagriSema helps people with excess body weight lose weight Ended recruitment
  2023-506929-11-00 5 2022-10-17 Overweight and obesity
• A Phase 3 Study of Rusfertide (PTG-300) in Patients with Polycythemia Vera Ended recruitment
  2023-509750-58-00 5 2022-09-21 Polycythemia Vera
• A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients with Paroxysmal Nocturnal … Ended recruitment
  2023-509657-31-00 5 2022-08-24 Paroxysmal nocturnal haemoglobinuria (PNH)
• A study to learn if Rozanolixizumab works and is safe over a long period in adults with relapsing myelin oligodendrocyte glycoprotein antibo … Ended recruitment
  2023-509237-39-00 5 2022-08-02 Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-A
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer ( … Ended recruitment
  2023-509260-25-00 5 2022-07-12 Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended recruitment
  2023-505974-14-00 5 2022-06-23 Multiple Sclerosis (MS)
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509345-12-00 5 2022-06-22 Multiple Sclerosis
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Myelin Oligodendrocyte Gly … Ended recruitment
  2023-507196-22-00 5 2022-06-20 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD
• GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t … Ended recruitment
  2023-504737-41-00 5 2022-06-10 Moderately to Severely Active Crohn's Disease
• A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended recruitment
  2023-505635-13-00 5 2022-06-10 Systemic lupus erythematosus
• Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery (MINS) - PREVENT-MINS Trial Ended recruitment
  2024-515226-81-00 5 2022-06-02 Myocardial Injury after Noncardiac Surgery
• A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati … Ended recruitment
  2023-503999-24-00 5 2022-06-01 Patients With Locally Advanced (Stage III), Unresectable Non-small Cel
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis Ended recruitment
  2023-506359-68-00 5 2022-04-08 Active Proliferative Lupus Nephritis
• A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended recruitment
  2024-511599-33-00 5 2021-12-22 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Showing 433–456 of 707 trials